“…In contrast, one of the most common drawbacks unrelated to the antibody size is associated with current conjugation chemistry, which can lead to the premature release of the toxic payload, causing off-target toxicity and decreasing the therapeutic window. , Here, GCE appears to be a straightforward solution to address both the heterogeneous product-formation and off-target toxicity issues, offering the potential to design ADCs with new modalities (improved properties). GCE has indeed emerged as a technology for creating ADCs with enhanced characteristics, introducing novel possibilities with examples such as ncAAs 12 , , 338 , , 337 , 70 , 13 , 63 , 65 , and 68 (all).…”